FirstString Competitors

Humacyte, Inc. (Nasdaq: HUMA) is proud to announce that in Dec 2024, FDA granted full approval for our Acellular Tissue Engineered Vessel (ATEV), a first-in-class, universally implantable, bioengineered human vessel for extremity arterial trauma. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries.See the Prescribing Information, including Boxed Warning: https://bit.ly/4dl5tuL This is the first approval in our bioengineered ATEV Platform where we are continuing to investigate use of our lab-grown tissues and organs to improve the lives of patients and transform the practice of medicine. We develop and manufacture acellular tissues that are meant to be universally implantable and remodel with the patient's own cells over time. The goal is to grow spare parts for people. Humacyte’s ATEV is in clinical trials for arteriovenous access for hemodialysis, and peripheral arterial disease. Investigational preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s ATEV for performing hemodialysis in AV Access was the first indication to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the ATEV technology received priority designation for the treatment of extremity arterial repair by the U.S. Secretary of Defense prior to its FDA approval in Dec 2024 for that purpose. For more information, visit https://Humacyte.com.

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', rebranded 'TRX BioSurgery' in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany. In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. India is an integral part of Lilly’s global footprint, contributing significantly to both local impact and global innovation. With an established presence in the country for over three decades, Lilly operates through three business entities in Gurgaon, Bengaluru, and Hyderabad. To better align our efforts and amplify our impact in India, we have implemented the ‘One India’ strategic framework. This approach brings all our entities under one vision, enabling seamless collaboration and reflecting our commitment to growth and innovation in India. Lilly in Gurgaon is present in India since 1993 and serves as a hub for our commercial operations. We drive the delivery of groundbreaking treatments across key therapeutic areas, including cardiometabolic health, oncology, and immunology. Through our pharmaceutical operations, we serve thousands of patients across the country, addressing critical health needs and improving patient outcomes. Lilly in Bengaluru stands as a critical global hub accelerating the development and delivery of innovative medicines through cross-functional collaboration and deep scientific expertise and enabling Lilly’s global success. The centre brings together capabilities from Lilly Research Laboratories, Commercial, and Tech@Lilly, enabling operational excellence and innovation at scale. Lilly in Hyderabad is poised to be a transformative force in our global strategy, driving innovation, efficiency, and growth. By leveraging advanced technologies such as automation, AI, software product engineering, and cloud computing, the centre is set to deliver cutting-edge solutions that will enhance our global operation. To learn more, visit https://www.lilly.com/in/